Opus Capital Group’s SELLAS Life Sciences SLS Stock Holding History

Opus Capital Group’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.69M	Buy	385,604 +39,152	+11%	+$270K	0.55%	33
2026 Q1	$1.47M	Buy	346,452 +29,352	+9%	+$131K	0.16%	50
2025 Q4	$1.2M	Buy	317,100 +67,100	+27%	+$130K	0.13%	52
2025 Q3	$403K	Buy	250,000 +10,000	+4%	+$17.8K	0.05%	84
2025 Q2	$526K	Buy	240,000 +500	+0.2%	+$767	0.06%	74
2025 Q1	$259K	Buy	239,500 +1,000	+0.4%	+$1.19K	0.03%	105
2024 Q4	$248K	Buy	238,500 +12,400	+5%	+$14.2K	0.03%	101
2024 Q3	$283K	Buy	226,100 +5,100	+2%	+$6.23K	0.04%	95
2024 Q2	$263K	Buy	221,000 +20,400	+10%	+$27.8K	0.04%	102
2024 Q1	$203K	Buy	200,600 +65,600	+49%	+$55.1K	0.03%	118
2023 Q4	$143K	Buy	135,000 +100,500	+291%	+$109K	0.02%	117
2023 Q3	$57K	Buy	34,500 +3,500	+11%	+$5.52K	0.01%	111
2023 Q2	$49K	Buy	31,000 +6,000	+24%	+$9.64K	0.01%	119
2023 Q1	$36K	Buy	25,000 +5,328	+27%	+$13.2K	0.01%	119
2022 Q4	$46K	Buy	+19,672	New	+$55.2K	0.01%	115

Other funds holding SLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Opus Capital Group's SLS Position: Q2 2026 in Review

Opus Capital Group increased its SELLAS Life Sciences (SLS) stake by 11% in Q2 2026, buying an estimated $270K and bringing the position to 385,604 shares worth $5.69M. The position accounts for 0.55% of the portfolio, ranked #33.

Opus Capital Group first reported a position in SLS in Q4 2022 and has held it in 15 quarters since. 192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

Opus Capital Group held 385,604 shares of SELLAS Life Sciences worth $5.69M as of Q2 2026.
Opus Capital Group bought 39,152 SELLAS Life Sciences shares in Q2 2026, an estimated $270K.
SELLAS Life Sciences made up 0.55% of Opus Capital Group's portfolio in Q2 2026, its #33 holding.
Opus Capital Group first reported a position in SELLAS Life Sciences in Q4 2022 and has held it in 15 quarters since.
192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Opus Capital Group's 13F filing for Q2 2026, filed 31 Jul 2026.